IBDEI1JY ; ; 19-NOV-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,25949,1,4,0)
 ;;=4^I83.029
 ;;^UTILITY(U,$J,358.3,25949,2)
 ;;=^5007986
 ;;^UTILITY(U,$J,358.3,25950,0)
 ;;=I83.91^^127^1269^4
 ;;^UTILITY(U,$J,358.3,25950,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,25950,1,3,0)
 ;;=3^Asymptomatic Varicose Veins Right Lower Extremity
 ;;^UTILITY(U,$J,358.3,25950,1,4,0)
 ;;=4^I83.91
 ;;^UTILITY(U,$J,358.3,25950,2)
 ;;=^5008020
 ;;^UTILITY(U,$J,358.3,25951,0)
 ;;=I83.92^^127^1269^3
 ;;^UTILITY(U,$J,358.3,25951,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,25951,1,3,0)
 ;;=3^Asymptomatic Varicose Veins Left Lower Extremity
 ;;^UTILITY(U,$J,358.3,25951,1,4,0)
 ;;=4^I83.92
 ;;^UTILITY(U,$J,358.3,25951,2)
 ;;=^5008021
 ;;^UTILITY(U,$J,358.3,25952,0)
 ;;=I83.93^^127^1269^2
 ;;^UTILITY(U,$J,358.3,25952,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,25952,1,3,0)
 ;;=3^Asymptomatic Varicose Veins Bilateral Lower Extremities
 ;;^UTILITY(U,$J,358.3,25952,1,4,0)
 ;;=4^I83.93
 ;;^UTILITY(U,$J,358.3,25952,2)
 ;;=^5008022
 ;;^UTILITY(U,$J,358.3,25953,0)
 ;;=M79.604^^127^1269^18
 ;;^UTILITY(U,$J,358.3,25953,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,25953,1,3,0)
 ;;=3^Right Limb Pain
 ;;^UTILITY(U,$J,358.3,25953,1,4,0)
 ;;=4^M79.604
 ;;^UTILITY(U,$J,358.3,25953,2)
 ;;=^5013328
 ;;^UTILITY(U,$J,358.3,25954,0)
 ;;=M79.605^^127^1269^12
 ;;^UTILITY(U,$J,358.3,25954,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,25954,1,3,0)
 ;;=3^Left Limb Pain
 ;;^UTILITY(U,$J,358.3,25954,1,4,0)
 ;;=4^M79.605
 ;;^UTILITY(U,$J,358.3,25954,2)
 ;;=^5013329
 ;;^UTILITY(U,$J,358.3,25955,0)
 ;;=Z13.6^^127^1269^19
 ;;^UTILITY(U,$J,358.3,25955,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,25955,1,3,0)
 ;;=3^Screening for Cardiovascular Disorders
 ;;^UTILITY(U,$J,358.3,25955,1,4,0)
 ;;=4^Z13.6
 ;;^UTILITY(U,$J,358.3,25955,2)
 ;;=^5062707
 ;;^UTILITY(U,$J,358.3,25956,0)
 ;;=B48.8^^127^1270^62
 ;;^UTILITY(U,$J,358.3,25956,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,25956,1,3,0)
 ;;=3^Mycoses NEC
 ;;^UTILITY(U,$J,358.3,25956,1,4,0)
 ;;=4^B48.8
 ;;^UTILITY(U,$J,358.3,25956,2)
 ;;=^5000689
 ;;^UTILITY(U,$J,358.3,25957,0)
 ;;=C49.9^^127^1270^60
 ;;^UTILITY(U,$J,358.3,25957,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,25957,1,3,0)
 ;;=3^Malig Neop of Connective/Soft Tissue,Unspec
 ;;^UTILITY(U,$J,358.3,25957,1,4,0)
 ;;=4^C49.9
 ;;^UTILITY(U,$J,358.3,25957,2)
 ;;=^5001136
 ;;^UTILITY(U,$J,358.3,25958,0)
 ;;=C85.80^^127^1270^66
 ;;^UTILITY(U,$J,358.3,25958,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,25958,1,3,0)
 ;;=3^Non-Hodgkin Lymphoma,Unspec Site NEC
 ;;^UTILITY(U,$J,358.3,25958,1,4,0)
 ;;=4^C85.80
 ;;^UTILITY(U,$J,358.3,25958,2)
 ;;=^5001721
 ;;^UTILITY(U,$J,358.3,25959,0)
 ;;=C85.89^^127^1270^65
 ;;^UTILITY(U,$J,358.3,25959,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,25959,1,3,0)
 ;;=3^Non-Hodgkin Lymphoma of Extranodal/Solid Organ Sites
 ;;^UTILITY(U,$J,358.3,25959,1,4,0)
 ;;=4^C85.89
 ;;^UTILITY(U,$J,358.3,25959,2)
 ;;=^5001730
 ;;^UTILITY(U,$J,358.3,25960,0)
 ;;=E11.9^^127^1270^22
 ;;^UTILITY(U,$J,358.3,25960,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,25960,1,3,0)
 ;;=3^Diabetes Type 2 w/o Complications
 ;;^UTILITY(U,$J,358.3,25960,1,4,0)
 ;;=4^E11.9
 ;;^UTILITY(U,$J,358.3,25960,2)
 ;;=^5002666
 ;;^UTILITY(U,$J,358.3,25961,0)
 ;;=E10.9^^127^1270^21
 ;;^UTILITY(U,$J,358.3,25961,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,25961,1,3,0)
 ;;=3^Diabetes Type 1 w/o Complications
 ;;^UTILITY(U,$J,358.3,25961,1,4,0)
 ;;=4^E10.9
 ;;^UTILITY(U,$J,358.3,25961,2)
 ;;=^5002626
 ;;^UTILITY(U,$J,358.3,25962,0)
 ;;=D50.0^^127^1270^57
 ;;^UTILITY(U,$J,358.3,25962,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,25962,1,3,0)
 ;;=3^Iron Deficiency Anemia Secondary to Blood Loss
